Table 3.

Clinical and genetic details of patients with objective response or prolonged stable disease^a

Patient ID	Age (y)	Histology	Genetic alteration	Other mutated genes	Tazemetostat dose	Best response	No. cycles	PFS (mo)	Reason for off- study treatment
11	3	ATRT	SMARCB1 loss	TSC1	1200 mg/m2	SD	13	13.7	Physician discretion
4	18	ES	SMARCB1 loss	None	1200 mg/m2	SD	9	7.8	PD
7	15	ES	SMARCB1 loss	None	520mg/m2	SD	26	28.3	Study completion
6	19	RMC	SMARCB1 loss	None	520mg/m2	SD	12	10.2	PD
3	10	Histiocytosis (Non-LCH)	SMARCA4 loss	None	1200 mg/m2	PR	25+	42.1	Physician discretion

^aATRT = atypical teratoid rhabdoid tumor; ES = epithelioid sarcoma; LCH = Langerhans cell histiocytosis; PD = progressive disease; PFS = progression-free survival; RMC = renal medullary carcinoma.